Zacks Research Research Analysts Boost Earnings Estimates for Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) – Equities research analysts at Zacks Research increased their Q3 2023 earnings estimates for Jazz Pharmaceuticals in a research note issued on Wednesday, August 23rd. Zacks Research analyst S. Ganoria now forecasts that the specialty pharmaceutical company will post earnings per share of $3.98 for the quarter, up from their previous estimate of $3.70. The consensus estimate for Jazz Pharmaceuticals’ current full-year earnings is $15.57 per share. Zacks Research also issued estimates for Jazz Pharmaceuticals’ Q4 2023 earnings at $4.22 EPS, FY2023 earnings at $15.21 EPS, Q1 2024 earnings at $3.60 EPS, Q2 2024 earnings at $4.05 EPS, Q3 2024 earnings at $4.44 EPS, Q4 2024 earnings at $4.62 EPS, FY2024 earnings at $16.72 EPS, Q1 2025 earnings at $4.00 EPS, Q2 2025 earnings at $4.43 EPS and FY2025 earnings at $18.15 EPS.

Several other research firms also recently commented on JAZZ. Needham & Company LLC reissued a “buy” rating and set a $226.00 price target on shares of Jazz Pharmaceuticals in a research note on Monday, August 7th. HC Wainwright reaffirmed a “buy” rating and issued a $204.00 target price on shares of Jazz Pharmaceuticals in a research note on Friday, August 11th. Royal Bank of Canada decreased their target price on shares of Jazz Pharmaceuticals from $203.00 to $201.00 and set an “outperform” rating on the stock in a research note on Thursday, August 10th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $180.00 target price on shares of Jazz Pharmaceuticals in a research note on Tuesday, August 22nd. Finally, StockNews.com began coverage on shares of Jazz Pharmaceuticals in a research note on Thursday, August 17th. They issued a “strong-buy” rating on the stock. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Jazz Pharmaceuticals has an average rating of “Buy” and an average price target of $206.67.

Jazz Pharmaceuticals Trading Up 1.8 %

JAZZ stock opened at $141.25 on Monday. The company has a market capitalization of $8.92 billion, a PE ratio of -89.97, a price-to-earnings-growth ratio of 1.01 and a beta of 0.73. Jazz Pharmaceuticals has a one year low of $120.64 and a one year high of $162.55. The company’s 50 day moving average price is $130.34 and its two-hundred day moving average price is $135.75. The company has a debt-to-equity ratio of 1.61, a quick ratio of 2.49 and a current ratio of 3.18.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. Tredje AP fonden raised its position in Jazz Pharmaceuticals by 5.4% in the 1st quarter. Tredje AP fonden now owns 13,352 shares of the specialty pharmaceutical company’s stock worth $1,954,000 after buying an additional 681 shares during the last quarter. Teacher Retirement System of Texas increased its position in shares of Jazz Pharmaceuticals by 33.9% during the 4th quarter. Teacher Retirement System of Texas now owns 11,941 shares of the specialty pharmaceutical company’s stock valued at $1,902,000 after purchasing an additional 3,026 shares during the last quarter. State Board of Administration of Florida Retirement System increased its position in shares of Jazz Pharmaceuticals by 0.7% during the 4th quarter. State Board of Administration of Florida Retirement System now owns 61,967 shares of the specialty pharmaceutical company’s stock valued at $9,872,000 after purchasing an additional 440 shares during the last quarter. Sei Investments Co. increased its position in shares of Jazz Pharmaceuticals by 16.1% during the 4th quarter. Sei Investments Co. now owns 57,428 shares of the specialty pharmaceutical company’s stock valued at $9,153,000 after purchasing an additional 7,975 shares during the last quarter. Finally, Franklin Resources Inc. increased its position in shares of Jazz Pharmaceuticals by 2.2% during the 4th quarter. Franklin Resources Inc. now owns 1,275,678 shares of the specialty pharmaceutical company’s stock valued at $203,228,000 after purchasing an additional 27,118 shares during the last quarter. Hedge funds and other institutional investors own 87.34% of the company’s stock.

Insider Activity

In other news, EVP Neena M. Patil sold 1,600 shares of the business’s stock in a transaction on Thursday, June 1st. The shares were sold at an average price of $127.98, for a total transaction of $204,768.00. Following the sale, the executive vice president now owns 32,826 shares in the company, valued at approximately $4,201,071.48. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In other news, EVP Neena M. Patil sold 750 shares of Jazz Pharmaceuticals stock in a transaction dated Tuesday, August 15th. The stock was sold at an average price of $139.59, for a total value of $104,692.50. Following the completion of the transaction, the executive vice president now owns 30,686 shares of the company’s stock, valued at approximately $4,283,458.74. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Neena M. Patil sold 1,600 shares of the business’s stock in a transaction dated Thursday, June 1st. The stock was sold at an average price of $127.98, for a total value of $204,768.00. Following the completion of the transaction, the executive vice president now directly owns 32,826 shares of the company’s stock, valued at approximately $4,201,071.48. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 3,875 shares of company stock worth $518,864. Corporate insiders own 4.40% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, such as hematologic and solid tumors.